Parisa Ebrahimisadr

Parisa Ebrahimisadr

Auto-generated profile, based on publicly available information

Parisa Ebrahimisadr

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2020 in BioImpacts
Verified
Journal Article
Open access
PDF file
PEParisa Ebrahimisadr
Parisa Ebrahimisadr
ZBZahra Bakhshandeh
Zahra Bakhshandeh
HMHamidreza Majidiani
Hamidreza Majidiani
Introduction: Thalassemia is associated with a genetic decline in the rate of synthesis of one or more types of natural hemoglobin polypeptide chains. One of the major complications in thalassemia patients is alloimmunization, which is antibody production by the patient against transfused red blood cells (RBCs). These RBCs are unknown by the recipient and the formed antibodies against them are called alloantibodies. This study aimed to evaluate the frequency of alloantibodies against RBCs in beta-thalassemia patients referred to Tehran Regional Blood Transfusion Center. Methods: In this study, antibody screening tests (Dia-cell I, II, and III) were performed on 184 thalassemia patients. An identification test by the Dia panel consisting of 11 different O RBCs groups to examine sera with Dia cells (I, II, or III) was performed. Results: In our study, males and females patients comprised 66 (35.87%) and 118 (64.13%), respectively, of whom 116 (63%) had alloimmunization. In addition, 68 thalassemia subjects (37%) lacked alloantibodies. Among 184 patients with beta-thalassemia major, anti-K (Kell system), anti-D, and anti-E (Rhesus system) had the most abundant alloantibody variants with an incidence of 24 (13%), 11 (5.98%), and 10 (5.4%), respectively. Conclusion: Before RBC transfusion, regular RBC antigen phenotypes, as well as problem-solving of alloantibody production by receiving compatible blood for Kell and RH subgroups, are suggested for all cases of transfusion-derived thalassemia.

8 November 2016 in Jundishapur Journal of Natural Pharmaceutical Products
Verified
Journal Article
Open access
PDF file
FGFatemeh Ghaffarifar
Fatemeh Ghaffarifar
PEParisa Ebrahimisadr
Parisa Ebrahimisadr
HMHamidreza Majidiani
Hamidreza Majidiani
FBFarahnaz Bineshian
Farahnaz Bineshian
FJFarnoosh Jameie
Farnoosh Jameie
EGEzatollah Ghasemi
Ezatollah Ghasemi
Background: Cutaneous Leishmaniasis (CL) is a serious threat to many endemic regions of the world, which may lead to some complications such as secondary infections, permanent scars, etc. Although there are available drugs, i.e. pentavalent antimony compounds for the treatment of CL, they are expensive, have side effects and/or there may be some drug-resistant species. Therefore, there is a tantalizing field of study to discover novel compounds against CL. In this study, we evaluated the leishmanicidal effects of Chaerophyllum plant extract on Leishmania major promastigotes in vitro. Methods: In each sterile 96-well plate, a volume of 100 λ of promastigotes was added. The three first wells lacked drug but contained drug solvents. Then, various concentrations of Chaerophyllum extract (6.25, 12.5, 25, 50, 100 and 200 µg/mL) were added to the parasite culture. Subsequently, the percentage of cytotoxicity of promastigotes and J774 macrophages were evaluated by the Microculture Tetrazolium Test (MTT) method. Also, the percentage of J774 macrophage apoptosis was assessed by flow cytometry. Results: The IC50 of Chaerophyllum extract was 80.62 µg/mL after 24 hours. The percentage of cytotoxicity of promastigotes and J774 macrophages after adding Chaerophyllum extract was 91% and 45%, respectively, by MTT. The percentage of apoptosis (early and late apoptosis) in macrophages induced by 50 and 100 μg/mL of Chaerophyllum extract after 24 hours was 0.01%, 0.13%, 0.01% and 0.1%, respectively. Conclusions: According to the MTT test, the concentration of 200 μg/mL of Chaerophyllum extract with 90% cytotoxicity was promising against L. major promastigotes and further studies are recommended to evaluate the effects of this plant.